Results 61 to 70 of about 149,648 (111)

Prehospital crushed versus integral prasugrel loading dose in STEMI patients with a large myocardial area. [PDF]

EuroIntervention
Wilschut JM, Vogel RF, Elscot JJ, Delewi R, Lemmert ME, van der Waarden NWPL, Nuis RJ, Paradies V, Alexopoulos D, Zijlstra F, Montalescot G, Angiolillo DJ, Krucoff MW, Smits PC, Vlachojannis GJ, Van Mieghem NM, Diletti R.   +16 more
europepmc   +1 more source

One-year body weight loss and gain as independent predictors of frailty-related outcomes and mortality in an aging Japanese population. [PDF]

Sci Rep
Fujii H, Kodani E, Kaneko T, Nakamura H, Tamura Y, Sasabe H.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

An overview of the utility of prasugrel hydrochloride as a treatment option for ischemic stroke

Expert Review of Neurotherapeutics, 2023
Prasugrel, a potent P2Y12 receptor inhibitor, is not currently recommended in patients with stroke due to a higher rate of recurrent stroke. Prasugrel was associated with comparable efficacy to clopidogrel in reducing the risk of ischemic stroke in a recent phase III study.The authors provide an overview of the potential role of prasugrel in the ...
Udaya S, Tantry, Sahib, Singh, Kevin P, Bliden, Paul A, Gurbel, William, Ashley   +4 more
openaire   +3 more sources

The Degradation Chemistry of Prasugrel Hydrochloride: Part 1—Drug Substance

Journal of Pharmaceutical Sciences, 2019
Prasugrel hydrochloride is the active ingredient in Effient™, a thienopyridine platelet inhibitor. An extensive study of the degradation chemistry of prasugrel hydrochloride (LY640315 hydrochloride) has been carried out on the drug substance (part I) and on the drug product (part II, future article) using a multidimensional approach including ...
Steven W, Baertschi, Lindsay, Maxwell-Backer, Matthew, Clemens, Tim A, Smitka, Jerry R, Draper, K Wayne, Taylor, Andreas, Kaerner, Patrick J, Jansen   +7 more
openaire   +3 more sources

Prasugrel hydrochloride for the treatment of sickle cell disease

Expert Opinion on Investigational Drugs, 2017
Therapeutic options for sickle cell disease (SCD) are limited and, currently, only one drug (hydroxyurea) has FDA approval for the treatment of adult SCD. While this genetic disease is caused by hemoglobin polymerization, subsequent downstream events trigger platelet activation, vaso-occlusion and the disease's complex pathophysiology.
Conran, Nicola, Rees, David C
openaire   +4 more sources

Acquired Factor V Inhibitor with Hemorrhagic Symptoms after Prasugrel Hydrochloride Treatment

Acta Haematologica, 2019
Acquired factor V inhibitor (AFVI) is a rare coagulopathy. It may be triggered by specific antigens such as antibiotics. We herein report the first case of AFVI after treatment with prasugrel hydrochloride (prasugrel) in an 80-year-old male who underwent percutaneous coronary intervention because of angina pectoris 6 years ago and was initiated on ...
Kazuki, Sakatoku, Teruhito, Takakuwa, Akiko, Miura, Taku, Araki, Yotaro, Fujitani, Ryosuke, Yamamura   +5 more
openaire   +3 more sources

Univariate and Multivariate Models for Determination of Prasugrel Base in the Formulation of Prasugrel Hydrochloride Using XRPD Method

Journal of Pharmaceutical Sciences, 2019
Prasugrel hydrochloride (PHCl) undergoes salt disproportionation, and the resulting prasugrel free base (PFB) may lead to the poor in vitro and or in vivo performance of the drug product. The aim of the present work was to develop univariate and multivariate models based on X-ray powder diffraction to quantify the salt and base in the powder and tablet
Sathish, Dharani, Sogra F, Barakh Ali, Hamideh, Afrooz, Mansoor A, Khan, Ziyaur, Rahman   +4 more
openaire   +3 more sources

Prasugrel hydrochloride for the treatment of acute coronary syndromes

Expert Opinion on Pharmacotherapy, 2015
P2Y12 receptor antagonists, by inhibiting platelet activation and subsequent aggregation, are critical to prevent ischemic event recurrence after an acute coronary syndrome (ACS). Prasugrel is a third-generation thienopyridine whose metabolites target the P2Y12 receptor.
Thibault, Lhermusier, Ron, Waksman
openaire   +3 more sources

Prasugrel hydrochloride for the treatment of acute coronary syndrome patients

Expert Review of Cardiovascular Therapy, 2016
Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically ...
Ashan, Gunarathne, Shahana, Hussain, Anthony H, Gershlick   +2 more
openaire   +3 more sources